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Abstract
Objective: To describe the clinical progress of women with vaginal atrophy who receive nonhormonal treatment. 
Material and methods: Single-center retrospective longitudinal observational descriptive study in postmenopau-
sal women aged 45-60 years with symptoms of vaginal atrophy who required nonhormonal treatment. 
Results: We included 98 women with a mean (SD) age of 54.6 (3.2) years and a mean time of 5.6 (3.0) years 
without menstrual periods. Of these, 63.3% were treated with hyaluronic acid and Centella asiatica cell lysate 
and the other 36.7% with glycerin and polycarbophil. The vaginal maturation index improved significantly after 3 
months of treatment with hyaluronic acid and Centella asiatica: the parabasal cell count declined (-8.4%; 95%CI, 
–10.6 to –6.2; p=0.001) and the intermediate cell count increased (3.6%; 95%CI, 2.0-5.3; p=0.001), as did that 
of superficial cells (4.8%; 95%CI, 3.8-5.7; p=0.001). In addition, all symptoms and signs of vaginal atrophy impro-
ved after 3 months with treatment with hyaluronic acid and Centella asiatica lysate. There was no significant 
change in the vaginal maturation index or in symptoms and signs after 3 months of treatment with glycerin and 
polycarbophil. 
Conclusions: Three months of nonhormonal treatment with hyaluronic acid and Centella asiatica lysate signifi-
cantly improved the vaginal maturation index.
Resumen
Objetivo: describir la evolución clínica de mujeres con atrofia vaginal que reciben un tratamiento no hormonal.
Material y métodos: estudio descriptivo observacional retrospectivo longitudinal unicéntrico en mujeres posme-
nopáusicas de 45 a 60 años con síntomas de atrofia vaginal que hubieran requerido tratamiento no hormonal.
Resultados: se incluyeron 98 mujeres con una edad media de 54,6 ± 3,2 años y un tiempo medio sin menstruación 
de 5,6 ± 3,0 años. El 63,3% de las mujeres eran tratadas con ácido hialurónico y lisado celular de centella asiática 
y el 36,7% con glicerol y policarbofil. El índice de maduración vaginal fue significativamente mejor tras tres meses 
de tratamiento con ácido hialurónico y lisado de centella asiática: descienden las células parabasales (-8,4%, 
IC95% (-10,6 – -6,2), p=0,001) y aumentan las intermedias (3,6%, IC95% (2,0 – 5,3), p=0,001) y las superficiales 
(4,8%, IC95% (3,8 – 5,7), p=0,001). Además, se redujeron todos los síntomas y signos de atrofia vaginal tras 3 
meses con el tratamiento con ácido hialurónico y lisado de centella asiática. No se encontraron cambios tras tres 
meses de tratamiento con glicerol y policarbofil en el índice de maduración vaginal y de los síntomas y signos.
Conclusiones: El tratamiento no hormonal con ácido hialurónico y lisado de centella asiática mejora significativa-
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INTRODUCTION
Vulvovaginal atrophy (VVA) is a chronic, progressive 
disease caused by reduced estrogen levels. It can appear 
at any time during a woman’s lifetime, although it is more 
common after the menopause, coinciding with estrogen 
deficiency (1). It affects almost 50% of peri- and post-
menopausal women, thus worsening their quality of 
life (2), and may be more common in specific subgroups 
of women such as survivors of breast cancer, where its 
prevalence exceeds 60% (1,3).
Changes in circulating estrogens are reflected in the 
physiology of the vagina and in the onset of symptoms 
at the level of the epithelium, which goes from being 
moist and thick with rugae to being smooth and thin as a 
result of the menopause and estrogen deficiency (1). The 
main changes that affect the vagina as a consequence of 
estrogen deficiency (4) are altered epithelial maturation 
with reduced superficial cells, reduced vaginal lactobacilli, 
increased pH with the subsequent risk of infections and 
inflammation, and reduced blood flow. These changes can 
affect the patient’s sexual health.
VVA is responsible for the onset of symptoms that a 
affect a woman’s quality of life (5). These symptoms inclu-
de dryness, irritation, itching, dyspareunia, frequent urina-
tion, urgency, and urge incontinence. Dyspareunia secon-
dary to vaginal atrophy plays a key role in female sexual 
dysfunction. In addition to the impact on sexuality and 
sexual relationships, vaginal atrophy affects urinary func-
tion and may impact activities of daily living (6). This wide 
range of effects has been reported to have a significant 
emotional impact and diminish the quality of life of post-
menopausal women. Therefore, VVA is associated with 
comorbid conditions such as depression and anxiety (7).
Despite evidence that around 50% of middle-aged 
postmenopausal women experience vaginal discomfort 
caused by VVA, vaginal health in middle-aged women is 
underestimated for many reasons (8), mostly because of 
ignorance about the extent to which VVA can affect sexual 
health and the quality of life of women and their partners.
The objective of treatment of VVA is to relieve symp-
toms, especially vaginal dryness. Currently available 
options include nonpharmacological approaches, espe-
cially changes in lifestyle, and pharmacological options 
(hormonal and nonhormonal products).
Available nonhormonal treatments include lubricants 
for dyspareunia and vaginal moisturizers for symptoms 
of VVA (1). Nonhormonal options are indicated mainly in 
women who wish to avoid hormone therapy or high-risk 
women with a history of hormone-sensitive malignant 
neoplasm, such as breast or endometrial cancer (4).
Lubricants consist mainly of a combination of protective 
and thickening agents in a water-soluble base. They are 
used principally for relief of vaginal dryness and discom-
fort during intercourse, thus providing relief in the short 
term (3). Their use is not expected to change the histologic 
characteristics of vaginal tissue, but to reduce the irrita-
tion caused by friction of tissue during sexual intercourse, 
that is, there will be no effect on maturation of the vaginal 
epithelium; therefore, use of lubricants does not reverse 
the atrophy-induced changes associated with estrogen 
deficiency.
Vaginal moisturizers rehydrate dry mucosal tissue, 
hydrate collagen, are absorbed by the epithelium, and 
adhere to the vaginal lining, thus mimicking natural vagi-
nal secretions, with improved vaginal moisture, elasticity, 
and pH. Vaginal moisturizers are indicated for the relief of 
vaginal dryness/atrophic vaginitis/vaginal atrophy. They 
are applied regularly (2-3 times per week). Their frequen-
cy of use is directly proportional to the severity of atrophy 
(ie, the worse the atrophy, the more frequent their use), 
and their effects last longer than lubricants (2-3 days) (3).
Although lubricants and moisturizers have proven effec-
tive, they differ in terms of composition. Therefore, it is 
important to choose the most appropriate lubricant or 
moisturizer and that which best adapts to the needs and 
specific situation of the patient (3).
Expert committees are showing increasing scientific 
interest in studying VVA, its determinants, and its impact 
on the quality of life and sex life of postmenopausal 
women. Therefore, the aim of the present study was to 
address this relevant question by attempting to descri-
be the microbiological and clinical progress of a group 
of women with vaginal atrophy receiving treatment with 
nonhormonal products.
MATERIAL AND METHODS
We performed a single-center, descriptive, longitudi-
nal, retrospective study of postmenopausal women aged 
45 to 60 years with symptoms of vaginal atrophy seen 
at the Gynecology Clinic of Hospital Universitario Sanitas 
la Zarzuela, Madrid, Spain between September 2016 and 
October 2017. The women had been using nonhormonal 
treatment for the previous year or less. We excluded all 
women who had received hormonal treatment or who 
had gynecological tumors, genital bleeding, pelvic organ 
prolapse grade >1, or active vaginal infection.
The study was presented to the Research Ethics Com-
mittee of Hospital Puerta de Hierro on April 8, 2016 and 
approved on July 26, 2016. All patients were managed 
according to standard clinical practice at the participating 
center. As this was an anonymous retrospective observa-
tional study, patient informed consent was not considered 
necessary, although where possible, every attempt was 
made to obtain it. We followed the ethical principles of the 
World Medical Association Declaration of Helsinki. 
Patients were included consecutively. The data collected 
from the clinical history at the center were demographic 
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characteristics (age, end of menstruation, profession), 
anthropometric data (weight, height, and body mass 
index), social habits (smoking, alcohol, sexual relations), 
disease history (prolapse, human papillomavirus [HPV], 
endocrine diseases [thyroid symptoms], and concomitant 
medication [antidepressants, antihistamines]). In addition, 
before beginning treatment and at 3 months after initia-
tion, we used an intensity scale (none, mild, moderate, 
intense, very intense) to record symptoms of vaginal atro-
phy (burning sensation, itching, dyspareunia, dryness) and 
signs (epithelial thinning, redness, inflammation, loss of 
rugae, stiffness, and fissures) and took a vaginal smear 
(superficial, intermediate, and parabasal cell count). Fina-
lly, the patient was questioned about her satisfaction with 
the nonhormonal treatment received (comfort, hygiene, 
ease of use, and degree of recommendation) using a 
Likert-type scale (very much against, against, neutral, in 
favor, very much in favor). 
The sample size was calculated based on changes in 
cytology (superficial, intermediate, and parabasal cells) at 
3 months after initiation of therapy (9). We calculated that 
it would be necessary to recruit 106 women to estimate 
the change in the vaginal maturation index (VMI) with an 
accuracy of 2.1 units, a 95% confidence interval, a power 
of 80%, and a dropout rate of 10%.
We used the VMI as an objective measure of vaginal 
atrophy. The VMI indicates the degree of maturity reached 
by the vaginal epithelium based on the type of exfoliat-
ed cells. Since it represents the percentage of parabasal, 
intermediate, and superficial cells, a shift to the left indi-
cates the presence of more immature cells on the surface 
(atrophy), whereas a shift to the right indicates the pres-
ence of more mature epithelia. 
Variables were analyzed for the total sample, and some 
of the characteristics were analyzed according to the 
nonhormonal treatment received. Categorical variables 
were expressed as absolute and relative frequencies and 
quantitative variables as mean (SD). In order to compare 
progress after 3 months of treatment, the estimation 
of the change was shown with its 95%CI. We applied a 
paired-samples t test or the Wilcoxon signed rank test in 
the case of a non-normal distribution. Statistical signifi-
cance was set at p<0.05. The analyses were performed 
using SAS© 9.4.
RESULTS
We included data from 98 women with vaginal atrophy 
who had started nonhormonal treatment. Since all of the 
patients fulfilled the selection criteria and completed the 
3-month follow-up, they were all included in the analy-
sis. Mean (SD) age was 54.6 (3.2) years, and mean time 
without menstruation was 5.6 (3.0) years. More than half 
(59.2%) worked outside the home. Nonsmokers accoun-
ted for 67.3%, and 75.5% did not consume alcohol. The 
patients had sexual relations a mean of 1.32 (0.6) times 
per week. As for concomitant conditions, 12.2% had gra-
de I prolapse, 8.2% had HPV infection, and 28.6% had a 
thyroid condition; 8.2% were taking antidepressants and 
1.0% antihistaminics.
The participants were divided into 2 groups: 63.3% 
took nonhormonal treatment based on hyaluronic acid 
and Centella asiatica cell lysate and 36.7% used treatment 
based on glycerin and polycarbophil. Baseline data for the 
whole sample and according to treatment are shown in 
Table I.
As for symptoms, before treatment, 75.5% of women 
felt a mild-moderate burning sensation, 45.9% mild 
itching, 78.6% moderate-intense dyspareunia, and 69.4% 
moderate-intense dryness. As for the signs, 74.5% presen-
ted moderate-intense thinning of the vaginal epithelium, 
51.1% mild-moderate redness, 24.5% mild inflammation, 
81.6% moderate-intense loss of rugae, 81.6% modera-
te-intense rigidity, and 23.5% mild fissures or erosions.
All of the signs and symptoms of vaginal atrophy 
improved after 3 months of nonhormonal treatment 
(Table II).
The VMI (parabasal/intermediate/superficial cells) in 
the total sample of 98 women was 90.4/7.4/2.2% at base-
line. After 3 months of treatment it was 85.0/9.5/5.5%. 
Therefore, the VMI was significantly better after 3 months 
of nonhormonal treatment (Table II), that is, parabasal 
cell values fell significantly (-5.4%; 95%CI, -7.1 to -3,7; 
p=0.001), and intermediate cell values increased signifi-
cantly (2.1%; 95%CI, 0.9-3.4; p=0.001), as did those of 
superficial cells (3.3%; 95%CI, 2.4-4.1; p=0.001). 
Comparison of the treatments showed that the VMI at 
baseline was 90.8/7.4/1.8% in women who used hyaluron-
ic acid and Centella asiatica; at 3 months, these values 
were 82.4/11.0/6.6%. Therefore, the VMI was significant-
ly improved after 3 months of treatment with hyaluronic 
acid and Centella asiatica, since values fell significantly 
for parabasal cells (-8.4%; 95%CI, -10.6 to -6.2; p=0.001) 
and increased for intermediate cells (3.6%; 95%CI, 2.0-
5.3; p=0.001) and superficial cells (4.8%; 95%CI, 3.8-5.7; 
p=0.001). 
In the group of patients who used glycerin and polycar-
bophil, the VMI did not vary significantly after 3 months 
of treatment. Values for parabasal cells decreased 0.25% 
(95%CI, -2.0 to 1.5), as did those of intermediate cells 
0.42% (95%CI -2.0 to 1.2), whereas superficial cells 
increased 0.67% (95%CI, -0.3 to 1.6).
After 3 months of treatment, signs and symptoms 
improved significantly for almost all of the variables ana-
lyzed, albeit with some differences in favor of the group 
that took hyaluronic acid and Centella asiatica. All signs 
and symptoms of vaginal atrophy improved after 3 months 
of treatment with hyaluronic acid and Centella asiatica 
(Table II), whereas with glycerin and polycarbophil, only 
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dyspareunia and vaginal dryness improved. In the case 
of signs, no significant changes were observed after 3 
months of treatment with glycerin and polycarbophil, 
except for the loss of vaginal rugae and loss of vaginal 
elasticity, which were reduced.
The satisfaction assessment indicated that more than 
90% of women were happy or very happy with hyaluronic 
acid and Centella asiatica for each of the items considered 
(comfort, hygiene, ease of use, and recommendation). 
Between 40% and 45% of women were satisfied or very 
satisfied with respect to comfort and hygiene with glycerin 
and polycarbophil, whereas 58.3% considered it easy or 
very easy to use. Among the women who used glycerin 
and polycarbophil, 2.8% would recommend it and 30.6% 
would not.
DISCUSSION
Our study analyzes the clinical progress of women with 
VVA after 3 months of treatment with a nonhormonal pro-
duct. The signs and symptoms recorded in our sample are 
consistent with those published in other studies on VVA 
(10). While many studies have demonstrated the effica-
cy of hormonal treatments for VVA and compare these 
with nonhormonal treatments, few have compared non-
Table I. 
Characteristics of the sample. Comparison between treatments used




Total patients, n (%) 98 62 (63.3) 36 (36.7)
Sociodemographic data, mean (SD)
 Age, y 54.6 (3.2) 54.7 (3.1) 54.4 (3.4)
  Age at end of menstruation, y 49.0 (2.7) 49.2 (2.9) 48.6 (2.3)
  Time without menstruation, y 5.6 (3.0) 5.6 (3.0) 5.7 (3.1)
  Sexual relations, times per week 1.3 (0.6) 1.3 (0.6) 1.4 (0.54)
Anthropometric data, mean (SD)
  Weight, kg 68.8 (8.1) 67.6 (8.3) 71.5 (7.3)
  Height, cm 165.7 (5.1) 165.2 (5.2) 166.5 (4.9)
  Body mass index, kg/m2 25.1 (2.7) 24.8 (2.8) 25.8 (2.2)
Social habits, n (%)
  Actively working outside the home 58 (59.2) 38 (61.3) 20 (55.6)
  Consumption of alcohol 24 (24.5) 19 (30.6) 5 (13.9)
  Smoking
   Never smoked 66 (67.3) 41 (66.1) 25 (69.4)
   Exsmoker 23 (23.5) 18 (29.0) 5 (13.9)
   Active smoker 9 (9.2) 3 (4.8) 6 (16.7)
History of vulvovaginal atrophy, n (%)
  Grade I prolapse 12 (12.2) 6 (9.7) 6 (16.7)
  Human papillomavirus 8 (8.2) 4 (6.5) 4 (11.1)
Concomitant endocrine diseases, n (%)
  Thyroid symptoms 28 (28.6) 15 (24.2) 13 (36.1)
Concomitant medication, n (%)
  Antidepressants 8 (8.2) 3 (4.8) 5 (13.9)
  Antihistamines 1 (1.0) 1 (1.6) 0 (0.0)
SD: Standard deviation.
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hormonal treatments, and none have included Centella 
asiatica (3).
Many guidelines now recommend nonhormonal pro-
ducts as first-line treatments for VVA. The Spanish Society 
of Gynecology and Obstetrics recommends vaginal moistu-
rizers supplemented with lubricants during intercourse as 
the first choice for mild-moderate symptoms of VVA (11). 
The North American Menopause Society considers non-
hormonal products the first choice for relief of symptoms 
of VVA and to facilitate regular sexual relations (12).
The ideal nonhormonal treatment would be charac-
terized by a moisturizing effect and have a maturational 
effect on the urogenital epithelium. The most widely used 
options are pectin- or polycarbophil polymer–based gels 
and compounds containing hyaluronic acid (2). In the 
present study, we compared 2 nonhormonal products by 
measuring changes in the symptoms of VVA, change in the 
VMI, and patient satisfaction (assessed using a subjective 
questionnaire).
Our study clearly shows an improvement in the symp-
toms associated with VVA resulting from treatment with 
a nonhormonal treatment based on hyaluronic acid and 
Centella asiatica. The results point to a significant impro-
vement in symptoms and signs of VVA after 3 months of 
treatment and, more specifically, to changes in the VMI, 
an objective measure of vaginal atrophy.
Hyaluronic acid–based products have a double lubri-
cating and moisturizing effect and have proven clinically 
successful in published studies (13). Moreover, hyaluronic 
acid is broadly effective in the treatment of skin diseases 
owing to the fact that it preserves tissue consistency, thus 
facilitating cell migration in cases of inflammation and the 
Table II.
Clinical progress after 3 months of treatment. Comparison between the treatments used




Hyaluronic acid and 




Vaginal maturation index (%)
  Parabasal cells -5.40 (-7.1 to 3.7)a -8.39 (-10.6 to 6.2)a -0.25 (-2.0 to 1.5)
  Intermediate cells 2.14 (0.9-3.4)a 3.63 (2.0-5.3)a -0.42 (-2.0 to 1.2)
  Superficial cells 3.26 (2.4-4.1)a 4.76 (3.8-5.7)a 0.67 (-0.3 to 1.6)
Symptoms1
  Burning/stinging -0.31 (-0.4 to 0.2)a -0.45 (-0.6 to 0.3)a -0.05 (-0.3 to 0.2)
  Vaginal itching -0.30 (-0.5 to 0.1)a -0.40 (-0.6 to 0.2)a -0.11 (-0.4 to 0.2)
  Dyspareunia -0.94 (-1.1 to 0.7)a -1.21 (-1.5 to 0.9)a -0.47 (-0.7 to 0.2) a
  Vaginal dryness -0.86 (-1.0 to 0.7)a -1.08 (-1.3 to 0.9)a -0.47 (-0.7 to 0.2)a
Signs1
  Epithelial thinning -0.48 (-0.6 – -0.3) a -0.66 (-0.8 – -0.5) a -0.17 (-0.4 – 0.1)
  Vaginal redness -0.24 (-0.4 – -0.1) a -0.44 (-0.6 – -0.3) a 0.08 (-0.1 – 0.3)
  Vaginal inflammation -0.15 (-0.3 – -0.1) a -0.24 (-0.4 – -0.1) a 0.00 (-0.2 – 0.2)
  Loss of vaginal rugae -0.52 (-0.6 – -0.4) a -0.67 (-0.8 – -0.5) a -0.25 (-0.5 – -0.0) a
  Loss of vaginal elasticity -0.70 (-0.9 – -0.5) a -0.97 (-1.2 – -0.8) a -0.25 (-0.5 – -0.1) a
  Vaginal erosions or fissures -0.28 (-0.4 – -0.1) a -0.35 (-0.5 – -0.2) a -0.14 (-0.4 – 0.1)
Satisfaction2
  Comfort 2.86 (2.7 – 3.0) 3.13 (2.9 – 3.3) 2.39 (2.2 – 2.6)
  Hygiene 3.00 (2.8 – 3.2) 3.35 (3.1 – 3.5) 2.39 (2.2 – 2.6)
  Ease of use 3.26 (3.1 – 3.4) 3.60 (3.4 – 3.8) 2.67 (2.5 – 3.0)
  Recommendation for treatment 2.62 (2.4 – 2.8) 3.15 (2.9 – 3.3) 1.72 (1.5 – 1.9)
1 Scale for symptoms and signs: 0, nonexistent; 1, mild; 2, moderate; 3, intense; 4, very intense.
2 Scale for satisfaction: 0, very much against; 1, against; 2, neutral; 3, in favor; 4, very much in favor.  
a p<0.05: Vaginal maturation index (paired-samples t test), symptoms, and signs (Wilcoxon). 95% confidence interval.
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process of improvement and regeneration of damaged 
tissues (2).
Other authors had already reported improvements 
in symptoms after treatment with hyaluronic acid (14), 
although the inclusion of Centella asiatica in this approach 
seems to have boosted the beneficial effects, as we show 
here. In vitro, the triterpenes of Centella have been pro-
ven to stimulate activation of fibroblasts and production of 
collagen I and III, which are key for wound healing owing 
to their re-epithelization effect (13).
A cytomorphometric analysis of vaginal smears from 
38 postmenopausal women treated with a polycar-
bophil vaginal moisturizer revealed an increase in the 
mean cell area, thus indicating a positive effect on the 
maturation of vaginal epithelium. However, there was 
no effect on the overall maturation index/value, thus 
revealing a lack of effect on vaginal morphology (15). Our 
results are consistent with this, since the VMI remained 
unchanged in patients who were treated with glycerin 
and polycarbophil. Products containing only glycerin 
and polycarbophil did not lead to changes in vaginal cell 
populations; therefore, the only improvements obser-
ved were in symptoms such as dyspareunia and vagi-
nal dryness. However, a significant improvement in the 
index was noted in patients treated with hyaluronic acid 
and Centella asiatica, thus highlighting the fundamental 
difference between the treatments. Therefore, these 
products have a more beneficial effect, since they act 
on the basis of the problem, thus leading to an impro-
vement in the symptoms and signs of VVA (perceived 
by patients as significant), that translates into very high 
patient satisfaction.
Our results are consistent with those published in the 
literature to date, with data from other studies being very 
similar to ours. Most are open-label trials, one trial is dou-
ble-blind, and another has a cross-over design. The studies 
generally last 6, 8, and 12 weeks, and sample size range 
from 15 to 200 participants (16).
The main limitation of the present study is its observa-
tional and retrospective design. Consequently, there is no 
placebo-controlled group, and this may limit our results. 
However, we performed an objective analysis of the signs 
of VVA and a vaginal smear study. In addition, as this was 
not a population-based study, we cannot guarantee that 
the study sample was representative of patients seen at 
gynecology clinics throughout Spain. However, we recrui-
ted a large number of patients in order to overcome this 
limitation. This information can be used in subsequent stu-
dies to construct models for the management of Spanish 
women with VVA.
In conclusion, the objectives of the present study were 
fulfilled, since we describe the clinical progress of women 
receiving nonhormonal treatment for VVA. Our results 
enable us to recommend products based on hyaluronic 
acid and Centella asiatica cell lysate.
CONCLUSIONS
A significant clinical improvement is observed after 3 
months of treatment with hyaluronic acid and Centella 
asiatica lysate. Therefore, this combination can be con-
sidered an effective and safe nonhormonal approach for 
the treatment of VVA.
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